Phosphorex, a US-based, drug delivery-focused contract development and manufacturing organisation (CDMO) and Ampersand Capital Partners portfolio company announced on Wednesday the appointment of Jerry Williamson as chief executive officer.

With over 35 years of leadership experience in bioscience and diagnostics, Williamson brings a proven track record of building innovative life sciences companies and delivering strong commercial and operational outcomes.

Most recently, Williamson served as CEO of Sengenics, where he led the company's strategic transformation in immunology profiling. He previously held CEO roles at NanoView Biosciences, KEW, Inc and Metamark Genetics, and served as president of Genetix LLC, Biacore Inc, and Pyrosequencing Inc. His expertise spans research tools, diagnostics and analytical technologies-sectors that Phosphorex says align strongly with its strategic growth ambitions.

"We're thrilled to welcome Jerry to the Phosphorex team," said Trevor Wahlbrink, general partner at Ampersand. "His exceptional leadership experience, particularly in scaling services platforms offering science-driven solutions, makes him ideally suited to lead Phosphorex through its next phase of innovation and expansion."

Williamson 's appointment comes as Phosphorex continues to expand its capabilities in lipid nanoparticle (LNP) formulation, process development and cGMP manufacturing to support the next generation of RNA, gene and small molecule therapeutics.